Limits...
Effectiveness of topical corticosteroids in addition to antiviral therapy in the management of recurrent herpes labialis: a systematic review and meta-analysis.

Arain N, Paravastu SC, Arain MA - BMC Infect. Dis. (2015)

Bottom Line: A fixed-effects model was used for mild to moderate heterogeneity, whereas a random-effects model was used for significant heterogeneity.The antiviral drugs used were acyclovir, famciclovir, and valacyclovir.Corticosteroids used were 1% hydrocortisone and 0.05% fluocinonide.

View Article: PubMed Central - PubMed

Affiliation: School of Health and Related Research, The University of Sheffield, Sheffield, UK. drnasra@gmail.com.

ABSTRACT

Background: Recurrent herpes labialis (RHL) is one of the most common viral infections worldwide. The available treatments have limited efficacy in preventing the recurrence of ulcerative lesions and reducing the duration of illness. The objective of this review was to identify the effectiveness of topical corticosteroids in addition to antiviral therapy in the treatment of RHL infection.

Methods: A systematic review of randomized clinical trials comparing the efficacy of combined therapy (topical corticosteroids with antiviral) with placebo or antiviral alone in the management of RHL was conducted. MEDLINE, EMBASE, CINAHL, Web of Science, the Cochrane library, and Google Scholar databases were searched. We used RevMan software to conduct the meta-analysis. A fixed-effects model was used for mild to moderate heterogeneity, whereas a random-effects model was used for significant heterogeneity. Heterogeneity among trials was established using I(2) and chi-square test for heterogeneity.

Results: Four studies that fulfilled the selection criteria were included in this review. The total number of participants across included studies was 1,891 (range, 29 to 1,443). The antiviral drugs used were acyclovir, famciclovir, and valacyclovir. Corticosteroids used were 1% hydrocortisone and 0.05% fluocinonide. Pooled results showed that patients receiving combined therapy had a significantly lower recurrence rate of ulcerative lesions compared to those in both the placebo group (OR, 0.50; 95% CI, 0.39-0.66; P < .001) and the antiviral treatment alone group (OR, 0.73, 95% CI, 0.58-0.92; P = .007). The healing time was also significantly shorter in combined therapy in comparison to placebo (P < .001). However, there were no significant differences in healing time between combined therapy and antiviral alone. The adverse reactions in combined therapy were not significantly different than the placebo group (OR, 1.09; 95% C, 0.75-1.59; P = .85).

Conclusion: Treatment with combined therapy is safe and more effective than placebo or antiviral alone for preventing the recurrence of ulcerative lesions in RHL infection.

Show MeSH

Related in: MedlinePlus

Forest plot of comparison: topical corticosteroid plus antiviral group versus placebo, outcome: Pooled odds ratio of development of ulcerative lesions.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4342818&req=5

Fig2: Forest plot of comparison: topical corticosteroid plus antiviral group versus placebo, outcome: Pooled odds ratio of development of ulcerative lesions.

Mentions: Three studies reported on this outcome [18-20]. There was no significant heterogeneity (I2 = 20%) found amongst trials (Figure 2). The chi-square test for heterogeneity was not significant (P = .29). Meta-analysis showed a statistically significant reduction in the development of ulcerative lesions, demonstrating that the odds of the occurrence of ulcerative lesions were 50% less likely in the intervention group as compared to placebo (OR, 0.50; 95% CI, 0.39-0.66; P < .001).Figure 2


Effectiveness of topical corticosteroids in addition to antiviral therapy in the management of recurrent herpes labialis: a systematic review and meta-analysis.

Arain N, Paravastu SC, Arain MA - BMC Infect. Dis. (2015)

Forest plot of comparison: topical corticosteroid plus antiviral group versus placebo, outcome: Pooled odds ratio of development of ulcerative lesions.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4342818&req=5

Fig2: Forest plot of comparison: topical corticosteroid plus antiviral group versus placebo, outcome: Pooled odds ratio of development of ulcerative lesions.
Mentions: Three studies reported on this outcome [18-20]. There was no significant heterogeneity (I2 = 20%) found amongst trials (Figure 2). The chi-square test for heterogeneity was not significant (P = .29). Meta-analysis showed a statistically significant reduction in the development of ulcerative lesions, demonstrating that the odds of the occurrence of ulcerative lesions were 50% less likely in the intervention group as compared to placebo (OR, 0.50; 95% CI, 0.39-0.66; P < .001).Figure 2

Bottom Line: A fixed-effects model was used for mild to moderate heterogeneity, whereas a random-effects model was used for significant heterogeneity.The antiviral drugs used were acyclovir, famciclovir, and valacyclovir.Corticosteroids used were 1% hydrocortisone and 0.05% fluocinonide.

View Article: PubMed Central - PubMed

Affiliation: School of Health and Related Research, The University of Sheffield, Sheffield, UK. drnasra@gmail.com.

ABSTRACT

Background: Recurrent herpes labialis (RHL) is one of the most common viral infections worldwide. The available treatments have limited efficacy in preventing the recurrence of ulcerative lesions and reducing the duration of illness. The objective of this review was to identify the effectiveness of topical corticosteroids in addition to antiviral therapy in the treatment of RHL infection.

Methods: A systematic review of randomized clinical trials comparing the efficacy of combined therapy (topical corticosteroids with antiviral) with placebo or antiviral alone in the management of RHL was conducted. MEDLINE, EMBASE, CINAHL, Web of Science, the Cochrane library, and Google Scholar databases were searched. We used RevMan software to conduct the meta-analysis. A fixed-effects model was used for mild to moderate heterogeneity, whereas a random-effects model was used for significant heterogeneity. Heterogeneity among trials was established using I(2) and chi-square test for heterogeneity.

Results: Four studies that fulfilled the selection criteria were included in this review. The total number of participants across included studies was 1,891 (range, 29 to 1,443). The antiviral drugs used were acyclovir, famciclovir, and valacyclovir. Corticosteroids used were 1% hydrocortisone and 0.05% fluocinonide. Pooled results showed that patients receiving combined therapy had a significantly lower recurrence rate of ulcerative lesions compared to those in both the placebo group (OR, 0.50; 95% CI, 0.39-0.66; P < .001) and the antiviral treatment alone group (OR, 0.73, 95% CI, 0.58-0.92; P = .007). The healing time was also significantly shorter in combined therapy in comparison to placebo (P < .001). However, there were no significant differences in healing time between combined therapy and antiviral alone. The adverse reactions in combined therapy were not significantly different than the placebo group (OR, 1.09; 95% C, 0.75-1.59; P = .85).

Conclusion: Treatment with combined therapy is safe and more effective than placebo or antiviral alone for preventing the recurrence of ulcerative lesions in RHL infection.

Show MeSH
Related in: MedlinePlus